% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{McCarthy:137108,
      author       = {McCarthy, James M and Appelhans, Dietmar and Tatzelt, Jörg
                      and Rogers, Mark S},
      title        = {{N}anomedicine for prion disease treatment: new insights
                      into the role of dendrimers.},
      journal      = {Prion},
      volume       = {7},
      number       = {3},
      issn         = {1933-6896},
      address      = {London [u.a.]},
      publisher    = {Taylor $\&$ Francis},
      reportid     = {DZNE-2020-03430},
      pages        = {198-202},
      year         = {2013},
      abstract     = {Despite their devastating impact, no effective therapeutic
                      yet exists for prion diseases at the symptomatic stage in
                      humans or animals. Progress is hampered by the difficulty in
                      identifying compounds that affect PrP (Sc) and the necessity
                      of any potential therapeutic to gain access to the CNS.
                      Synthetic polymers known as dendrimers are a particularly
                      promising candidate in this area. Studies with cell culture
                      models of prion disease and prion infected brain homogenate
                      have demonstrated that numerous species of dendrimers
                      eliminate PrP (Sc) in a dose and time dependent fashion and
                      specific glycodendrimers are capable of crossing the CNS.
                      However, despite their potential a number of important
                      questions remained unanswered such as what makes an
                      effective dendrimer and how dendrimers eliminate prions
                      intracellularly. In a number of recent studies we have
                      tackled these questions and revealed for the first time that
                      a specific dendrimer can inhibit the intracellular
                      conversion of PrP (C) to PrP (Sc) and that a high density of
                      surface reactive groups is a necessity for dendrimers in
                      vitro anti-prion activity. Understanding how a therapeutic
                      works is a vital component in maximising its activity and
                      these studies therefore represent a significant development
                      in the race to find effective treatments for prion
                      diseases.},
      keywords     = {Animals / Dendrimers: chemistry / Dendrimers: pharmacology
                      / Dendrimers: therapeutic use / Humans / Nanomedicine /
                      Prion Diseases: drug therapy / Prion Diseases: metabolism /
                      Prions: antagonists $\&$ inhibitors / Prions: chemistry /
                      Prions: metabolism / Protein Conformation: drug effects /
                      Dendrimers (NLM Chemicals) / Prions (NLM Chemicals)},
      cin          = {Ext AG Tatzelt},
      ddc          = {570},
      cid          = {I:(DE-2719)5000053},
      pnm          = {342 - Disease Mechanisms and Model Systems (POF3-342)},
      pid          = {G:(DE-HGF)POF3-342},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:23764833},
      pmc          = {pmc:PMC3783103},
      doi          = {10.4161/pri.24431},
      url          = {https://pub.dzne.de/record/137108},
}